Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

La Jolla Pharmaceutical Co

+ Add to Watchlist

LJPC:US

19.2400 USD 0.6600 3.55%

As of 20:10:00 ET on 03/26/2015.

Snapshot for La Jolla Pharmaceutical Co (LJPC)

Open: 18.4000 Day's Range: 17.9500 - 19.8300 Volume: 161,920
Previous Close: 18.5800 52wk Range: 6.1700 - 24.8900 1-Yr Rtn: +80.15%

Stock Chart for LJPC

No chart data available.
  • LJPC:US 19.2400
  • 1D
  • 1M
  • 1Y
18.5800
Interactive LJPC Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for LJPC

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -2.4900
Est. EPS (USD) (12/2015) -2.0530
Est. PEG Ratio -
Market Cap (M USD) 293.28
Shares Outstanding (M) 15.24
30 Day Average Volume 142,833
Price/Book (mrq) 7.0182
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/30/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for LJPC

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for LJPC

La Jolla Pharmaceutical Company researches and develops specialized therapeutics for the treatment of diseases caused by antibodies. The Company is developing products to treat autoimmune conditions such as lupus and antibody-mediated stroke.

George F TidmarshPresident/CEO/Secretary
More Company Profile & Key Executives for LJPC

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil